10x Genomics, Inc…
USUSD10x Genomics, Inc. (US:TXG) — Biotechnology: Laboratory Analytical Instruments. Börside arv, kus ettevõtte aktsiatega kaubeldakse: 2. Sellel lehel — hind ja graafik, dividendid, suurimad aktsionärid ja aktsiate arvu ajalugu.
Ettevõtte kohta
- Veebileht
- 10xgenomics.com
- Sektor
- Industrials · Biotechnology: Laboratory Analytical Instruments
- Peakontor
- Pleasanton, United States
- Tegevjuht
- Dr. Serge Saxonov Ph.D.
- Töötajad
- 1 178
- Asutatud
- 2012
- Ringluses olevad aktsiad
- 120.21 mln
- Vabalt kaubeldavad aktsiad
- 118.19 mln
- Turukapitalisatsioon
- 11.53 mld USD
- Siseringi isikud
- 1.46%
- Institutsionaalsed investorid
- 120.2%
- Tegevusala (SIC)
- Laboratory Analytical Instruments
- ISIN
- US88025U1097
- LEI
- 5493003Z6741WNLG7H43
Kirjeldus
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Dividendid
Dividendimakseid ei leitud (kontrollitud 09.10.2026). Ettevõte ilmselt dividende ei maksa.
Selle nädala uudised
Ettevõtte veebisaidilt uudiseid veel pole.
Suurimad omanikud
| Omanik | Osalus | Aktsiad | Aruande kuupäev |
|---|---|---|---|
| FMR, LLC | 14.67% | 17.63 mln | 2026-06-30 |
| Blackrock Inc. | 8.99% | 10.8 mln | 2026-06-30 |
| ARK Investment Managemen… | 8.32% | 10 mln | 2026-06-30 |
| Vanguard Portfolio Manag… | 5.81% | 6.98 mln | 2026-06-30 |
| Quantinno Capital Manage… | 4.55% | 5.47 mln | 2026-06-30 |
| Vanguard Capital Managem… | 4.23% | 5.08 mln | 2026-06-30 |
| Price (T.Rowe) Associate… | 3.78% | 4.54 mln | 2026-06-30 |
| Sumitomo Mitsui Trust Gr… | 3.49% | 4.19 mln | 2026-06-30 |
| Amova Asset Management A… | 3.49% | 4.19 mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.94% | 3.53 mln | 2026-06-30 |
| Morgan Stanley | 2.79% | 3.35 mln | 2026-06-30 |
| iShares Trust-iShares Ru… | 2.53% | 3.04 mln | 2026-07-31 |
| ARK ETF Trust-ARK Genomi… | 2.53% | 3.04 mln | 2026-08-31 |
| ARK ETF Trust-ARK Innova… | 2.5% | 3.01 mln | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 2.12% | 2.55 mln | 2026-06-30 |
| Fidelity Select PORT.s-S… | 1.66% | 2 mln | 2026-07-31 |
| Fidelity Rutland Square… | 1.37% | 1.65 mln | 2026-07-31 |
| Fidelity Select Portfoli… | 1.34% | 1.61 mln | 2026-07-31 |
| VANGUARD INDEX FUNDS-Van… | 1.22% | 1.47 mln | 2026-06-30 |
| T. Rowe Price New Horizo… | 1.21% | 1.46 mln | 2026-06-30 |
| SAXONOV SERGE WILSON (Ch… | ≈1.11% | 1.34 mln | 2026-09-22 |
| HINDSON BENJAMIN J (Pres… | ≈0.41% | 488 182 | 2026-08-24 |
| STUELPNAGEL JOHN R (Dire… | ≈0.27% | 328 436 | 2026-09-03 |
| TAICH ADAM (Chief Financ… | ≈0.26% | 316 344 | 2026-09-09 |
| MATEO ALAN V. (Director) | ≈0.07% | 85 877 | 2026-06-04 |
| KOSARAJU SRIDHAR (Direct… | ≈0.06% | 68 278 | 2026-06-04 |
| POPOVITS KIMBERLY J (Dir… | ≈0.03% | 37 445 | 2026-06-04 |
| TEICHMANN SARAH A. (Dire… | ≈0.02% | 28 058 | 2026-08-14 |
| SULIMAN SHEHNAAZ (Direct… | ≈0.02% | 23 792 | 2026-09-22 |